12/ Going back to the original data, here's the reason evening dosing is superior for lovastatin and simvastatin:
🔑These statins have short half-lives. By giving them at night, you ensure they work on their target enzyme (HMG CoA reductase) when its activity is highest.
13/ Does it matter that many still default to evening dosing of ALL statins, despite little to no difference for long-acting versions?
Given that some data shows that adherence is higher for morning medications, it just might.
14/ Before closing, I'm again curious: what will you do now?
Will do prescribe/order/take only in the morning (to increase adherence), evening (maybe it's better), modify based on the statin half-life, or ask the patient what you'd prefer?
15/15
☞ HMG CoA reductase activity is highest overnight
☞ Based on this, statins with short half-lives may be more effective when taken at night
☞ For statins with longer half-lives, timing likely does not matter
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/9 🤔 Why doesn't an elevated BUN lead to extreme thirst? If increased serum osmolarity compels us to seek water, uremia should be a significant driver of this craving.
And yet, it isn't.
Let's examine why.
2/
We've known for nearly a century that an increase in serum urea is not a significant driver of thirst.
In 1937, Alfred Gilman published an experiment in which dogs received an IV injection of either:
➤20% NaCl
➤40% urea
3/
After 30 minutes, the dogs were offered water, and had blood work drawn. Gilman made two key observations:
🔑 The increase in serum osmolarity with hypertonic NaCl and urea were nearly identical
🔑 Dogs drank significantly more water after hypertonic NaCl injection
You are seeing a patient recently diagnosed with heart failure and started on GDMT. You notice that their hemoglobin (HGB) has increased (12 → 13 g/dL) in the intervening weeks.
🤔Which medication is the likely cause of this increase in HGB?
2/12 - An Answer
Empagliflozin
💡All SGLT2 inhibitors have been associated with an increase in hematocrit/hemoglobin soon after initiation.
The average increase is 2.3% in hematocrit and 0.6 g/dL in hemoglobin.
The effect of SGLT2 inhibitors on HCT/HGB has been noted since the very first randomized control trial of dapagliflozin, published in 2010.
Initially, investigators assumed this was related to the diuretic effect of these drugs (i.e., a reduction in plasma volume led to an increase in HCT/HGB).